This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kewn, S.
Right arrow Articles by Back, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kewn, S.
Right arrow Articles by Back, D. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2002, p. 135-143, Vol. 46, No. 1
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.1.135-143.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Development of Enzymatic Assays for Quantification of Intracellular Lamivudine and Carbovir Triphosphate Levels in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Patients

Stephen Kewn,* Patrick G. Hoggard, Sean D. Sales, Kevin Jones, Bridget Maher, Saye H. Khoo, and David J. Back

Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, L69 3GE, United Kingdom

Received 24 April 2001/ Returned for modification 2 August 2001/ Accepted 1 October 2001

In this paper, we describe the development and use of enzymatic assays to determine intracellular lamivudine triphosphate (3TCTP) and carbovir triphosphate (CBVTP) concentrations in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus (HIV)-infected patients. The assays involve inhibition of HIV reverse transcriptase (RT), which normally incorporates radiolabeled deoxynucleoside triphosphates into a synthetic template primer. For the 3TCTP assay, a preincubation procedure was added whereby 3TCTP becomes incorporated before [3H]dCTP. At a 1:400 template primer dilution, control product formation was reduced by 88.0% with 0.8 pmol of 3TCTP. Standard 3TCTP inhibition curves were performed using this procedure. For the CBVTP assay, 0.1 pmol of CBVTP inhibited control product formation with and without the use of a preincubation step, so inhibition curves were constructed using both procedures. However, reduced template primer stability with assays using preincubation steps led to a single-incubation procedure being adopted for future studies. The presence of PBMC extracts interfered with the 3TCTP assay. However, this was overcome by the addition of CuSO4. PBMC extracts did not interfere with the CBVTP assay. Intracellular 3TCTP and CBVTP concentrations were determined in PBMCs from HIV-infected patients over 24 h or greater. Peak concentrations were obtained 6 to 8 h after dosing, and the half-lives of the anabolites suggested the possibility of once-daily dosing. These assays are currently being used for determination of 3TCTP and CBVTP concentrations in clinical studies.

* Corresponding author. Mailing address: Department of Pharmacology & Therapeutics, New Medical Building, University of Liverpool, Ashton St., Liverpool, L69 3GE, United Kingdom. Phone: (0151) 794-5565. Fax: (0151) 794-5540. E-mail: Kewny{at}liverpool.ac.uk.

Antimicrobial Agents and Chemotherapy, January 2002, p. 135-143, Vol. 46, No. 1
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.1.135-143.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Rodriguez-Torres, M., Torriani, F. J., Soriano, V., Borucki, M. J., Lissen, E., Sulkowski, M., Dieterich, D., Wang, K., Gries, J.-M., Hoggard, P. G., Back, D., for the APRICOT Study Group, (2005). Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study. Antimicrob. Agents Chemother. 49: 3997-4008 [Abstract] [Full Text]  
  • Anderson, P. L (2004). Pharmacologic Perspectives for Once-Daily Antiretroviral Therapy. The Annals of Pharmacotherapy 38: 1924-1934 [Abstract] [Full Text]  
  • Saavedra-Lozano, J., McCoig, C. C., Cao, Y., Vitetta, E. S., Ramilo, O. (2004). Zidovudine, Lamivudine, and Abacavir Have Different Effects on Resting Cells Infected with Human Immunodeficiency Virus In Vitro. Antimicrob. Agents Chemother. 48: 2825-2830 [Abstract] [Full Text]  
  • Kewn, S., Wang, L. H., Hoggard, P. G., Rousseau, F., Hart, R., MacNeela, J. P., Khoo, S. H., Back, D. J. (2003). Enzymatic Assay for Measurement of Intracellular DXG Triphosphate Concentrations in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus Type 1-Infected Patients. Antimicrob. Agents Chemother. 47: 255-261 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»